Drug Trial Radar · NCT04568434
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS)
Last checked: Nov 20, 2026Latest source record: Mar 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
66
Actual
Start
Nov 18, 2020
Primary completion
Jul 14, 2023
Study completion Oct 17, 2023
Sponsor
- Lead sponsor
- Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
- Sponsor type
- Industry
- First posted
- Sep 29, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study was to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from baseline.
Conditions
- Familial Chylomicronemia Syndrome
Interventions
OlezarsenDrug
Olezarsen was administered by SC injection.
PlaceboDrug
Olezarsen-matching placebo was administered by SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in Fasting TG at Month 6Time frame: Baseline, Month 6
Locations
47 sites in 11 countries. Site status is shown where the registry gives one.
Diabetes/Lipid Management & Research Center
Huntington Beach, California
University of California, San Francisco (UCSF) - Medical Center
San Francisco, California
Excel Medical Clinical Trials, LLC
Boca Raton, Florida
NorthShore University Health System
Evanston, Illinois
Advocate Health and Hospitals Corporation - Lutheran General Hospital
Park Ridge, Illinois
Ascension St. Vincent Cardiovascular Research Institute
Indianapolis, Indiana
University of Kansas Medical Center (KUMC)
Kansas City, Kansas
University of Michigan- Endocrinology & Metabolism
Ann Arbor, Michigan
New York University (NYU) Langone Medical Center
New York, New York
Columbia University Medical Center
New York, New York
Moses H. Cone Memorial Hospital
Greensboro, North Carolina
University of Pennsylvania
Philadelphia, Pennsylvania
Vanderbilt University
Nashville, Tennessee
University of Texas Southwestern
Dallas, Texas
Baylor College of Medicine
Houston, Texas
York Clinical Research LLC
Norfolk, Virginia
West Virginia University Heart and Vascular Institute
Morgantown, West Virginia
Institute de Recherches Cliniques de Montreal
Montreal, Canada
Ecogene-21
Chicoutimi, Quebec, Canada
Nathalie Saint-Pierre
Montreal, Quebec, Canada
Clinique des Maladies Lipidiques de Quebec Inc.
Québec, Quebec, Canada
Hôpital Louis Pradel - HCL
Bron, France
CHU Dijon - Bocage
Dijon, France
Assistance Publique - Hopitaux de Marseille
Marseille, France
ASST Grande Ospedale Metropolitano Niguarda
Milan, Italy
Azienda Ospedaliera Universitaria Federico II
Naples, Italy
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
Palermo, Italy
Azienda Ospedaliero Universitaria Policlinico Umberto I
Roma, Italy
Academic Medical Center - Department of Vascular Medicine
Amsterdam, Netherlands
Erasmus MC
Rotterdam, Netherlands
Universitair Medisch Centrum Utrecht
Utrecht, Netherlands
The Lipid Clinic (Oslo University Hospital)
Oslo, Norway
Centro Hospitalar de Lisboa Ocidental. E.P.E, - Hospital Santa Cruz
Carnaxide, Portugal
Hospital da Senhora da Oliveira - Guimaraes
Creixomil, Portugal
Centro Hospitalar de Lisboa Ocidental, EPE - Hospital Egas Moniz
Lisbon, Portugal
Metabolicke centrum MUDr Katariny Raslovej s. r. o.
Bratislava, Slovakia
Hospital Abente y Lago
A Coruña, Spain
Hospital Clinic Barcelona
Barcelona, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Universitario Virgen del Rocio
Seville, Spain
Showing 40 of 47 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.